NAMS WACC: 8.24% for NewAmsterdam Pharma Company N.V. Ordinary Shares
Current inputs imply a 8.24% cost of equity and a 5.00% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.
WACC Calculator
Values are automatically populated from real data. You can adjust them manually if needed.
Please enter a valid company ticker to calculate WACC
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) WACC in context
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) currently screens with an estimated WACC of 8.24%. That blends a 8.24% cost of equity, a 5.00% pre-tax cost of debt, and a 100.00% equity weight into the discount rate you would typically use in a DCF model.
falls into a common range for established public companies and is a practical DCF starting point.
A 8.24% discount rate falls into a common range for established public companies and is a practical DCF starting point.
This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 0.83 and equity accounts for 100.00% of capital.
Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.